Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PRNP | P04156 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | G6PD | P11413 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4462858 | 0.74 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL16289018 | 0.74 | CA2 (0.35) | SMN1; SMN2ALDH1A1KDM4ENPC1LMNA | |
| SCHEMBL16288990 | 0.69 | — | — | |
| SCHEMBL16289818 | 0.69 | TSHR (0.33) | ALDH1A1KDM4E | |
| SCHEMBL4463054 | 0.69 | CA2 (0.39) | SMN1; SMN2ALDH1A1GAAKDM4EMEN1 | |
| SCHEMBL16288095 | 0.69 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL5538829 | 0.66 | ALDH1A1 (0.43) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL4459911 | 0.65 | — | — | |
| SCHEMBL5543966 | 0.64 | MPL (0.31) | — | |
| SCHEMBL8611683 | 0.64 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1GAAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737815-B1 | THIO-SUBSTITUTED BIARYL-METHANESULFINYL DERIVATIVES | CEPHALON INC (US) | 2016-12-21 | — | — | EP | claimed |
| US-7981907-B2 | Thio-substituted biarylmethanesulfinyl derivatives | CEPHALON, INC. (US) | 2011-07-19 | — | — | US | claimed |
| US-7449481-B2 | e.g. 2-[2-(5-chloro-benzo[b]thiophen-2-yl)-phenylmethanesulfinyl]-acetamide; autoimmune disorders, antidepressant; narcolepsy, Parkinson's, Alzheimer's disease; attention deficit hyperactivity disorder; sleep disorder, fatigue | CEPHALON, INC. (US) | 2008-11-11 | — | — | US | claimed |
| EP-2952096-B1 | Amide compound, an arthropod pest control agent and a method for controlling arthropod pest | SUMITOMO CHEMICAL CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9814235-B2 | Method for controlling arthropod pest | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-14 | — | — | US | disclosed |
| EP-1737815-B1 | THIO-SUBSTITUTED BIARYL-METHANESULFINYL DERIVATIVES | CEPHALON INC (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2952096-A1 | METHOD FOR CONTROLLING ARTHROPOD PEST | Sumitomo Chemical Company, Limited (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-20150344466-A1 | METHOD FOR CONTROLLING ARTHROPOD PEST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-12-03 | — | — | US | disclosed |
| US-20150005348-A1 | AMIDE COMPOUND AND USE THEREOF FOR PEST CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-01-01 | — | — | US | disclosed |
| EP-2813492-A1 | AMIDE COMPOUND AND USE THEREOF FOR PEST CONTROL | Sumitomo Chemical Co., Ltd (JP) | 2014-12-17 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7157465-B2 | Adenine derivatives | DAINIPPON SIMITOMO PHARMA CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1250548-C | Novel adenine derivatives | SUMITOMO PHARMA (JP) | 2006-04-12 | — | — | CN | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1512992-A | Novel adenine derivatives | ס����ҩ��ʽ���� | 2004-07-14 | — | — | CN | disclosed |
| US-20040132748-A1 | Novel adenne derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | SMN1; SMN2 3985/4885ALDH1A1 355/4885GAA 4165/4885 |
| US-20150344466-A1 | METHOD FOR CONTROLLING ARTHROPOD PEST | H1-0, H1-3, H1-2 | SMN1; SMN2 2187/4885ALDH1A1 3053/4885GAA 4201/4885 |
| US-20150005348-A1 | AMIDE COMPOUND AND USE THEREOF FOR PEST CONTROL | RPS8, MT-CO2, ARG1 | SMN1; SMN2 3476/4885ALDH1A1 3265/4885GAA 4190/4885 |
| US-20040132748-A1 | Novel adenne derivatives | IRF3, IFNAR1, STING1 | SMN1; SMN2 3339/4885ALDH1A1 1181/4885GAA 3040/4885 |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | IRF3, IFNAR1, IFNG | SMN1; SMN2 3105/4885ALDH1A1 2467/4885GAA 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.